{"id":28424,"date":"2020-07-14T05:41:32","date_gmt":"2020-07-14T05:41:32","guid":{"rendered":"https:\/\/www.healthbenefitstimes.com\/glossary\/?p=28424"},"modified":"2020-07-14T05:41:32","modified_gmt":"2020-07-14T05:41:32","slug":"noradrenergic-and-specific-serotonergic-antidepressants-nassas","status":"publish","type":"post","link":"https:\/\/www.healthbenefitstimes.com\/glossary\/noradrenergic-and-specific-serotonergic-antidepressants-nassas\/","title":{"rendered":"Noradrenergic and specific serotonergic antidepressants (NaSSAs)"},"content":{"rendered":"<p>A class of atypical antidepressants that exert their effects by antagonizing presynaptic alpha2 receptors of both noradrenergic and serotonergic neurons, resulting in enhanced neurotransmission of norepinephrine and serotonin. NaSSAs are used primarily for the treatment of depression and anxiety disorders. An example of an NaSSA is mirtazapine (remeron).<\/p>\n<hr \/>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A class of atypical antidepressants that exert their effects by antagonizing presynaptic alpha2 receptors of both noradrenergic and serotonergic neurons, resulting in enhanced neurotransmission of norepinephrine and serotonin. NaSSAs are used primarily for the treatment of depression and anxiety disorders. An example of an NaSSA is mirtazapine (remeron). &nbsp;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[14],"tags":[],"class_list":["post-28424","post","type-post","status-publish","format-standard","hentry","category-n"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Noradrenergic and specific serotonergic antidepressants (NaSSAs) - Definition of Noradrenergic and specific serotonergic antidepressants (NaSSAs)<\/title>\n<meta name=\"description\" content=\"A class of atypical antidepressants that exert their effects by antagonizing presynaptic alpha2 receptors of both noradrenergic and serotonergic neurons, resulting in enhanced neurotransmission of norepinephrine and serotonin. NaSSAs are used primarily for the treatment of depression and anxiety disorders. An example of an NaSSA is mirtazapine (remeron).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.healthbenefitstimes.com\/glossary\/noradrenergic-and-specific-serotonergic-antidepressants-nassas\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Noradrenergic and specific serotonergic antidepressants (NaSSAs) - Definition of Noradrenergic and specific serotonergic antidepressants (NaSSAs)\" \/>\n<meta property=\"og:description\" content=\"A class of atypical antidepressants that exert their effects by antagonizing presynaptic alpha2 receptors of both noradrenergic and serotonergic neurons, resulting in enhanced neurotransmission of norepinephrine and serotonin. NaSSAs are used primarily for the treatment of depression and anxiety disorders. An example of an NaSSA is mirtazapine (remeron).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.healthbenefitstimes.com\/glossary\/noradrenergic-and-specific-serotonergic-antidepressants-nassas\/\" \/>\n<meta property=\"og:site_name\" content=\"Glossary\" \/>\n<meta property=\"article:published_time\" content=\"2020-07-14T05:41:32+00:00\" \/>\n<meta name=\"author\" content=\"Glossary\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Glossary\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/noradrenergic-and-specific-serotonergic-antidepressants-nassas\/\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/noradrenergic-and-specific-serotonergic-antidepressants-nassas\/\",\"name\":\"Noradrenergic and specific serotonergic antidepressants (NaSSAs) - Definition of Noradrenergic and specific serotonergic antidepressants (NaSSAs)\",\"isPartOf\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#website\"},\"datePublished\":\"2020-07-14T05:41:32+00:00\",\"dateModified\":\"2020-07-14T05:41:32+00:00\",\"author\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5\"},\"description\":\"A class of atypical antidepressants that exert their effects by antagonizing presynaptic alpha2 receptors of both noradrenergic and serotonergic neurons, resulting in enhanced neurotransmission of norepinephrine and serotonin. NaSSAs are used primarily for the treatment of depression and anxiety disorders. An example of an NaSSA is mirtazapine (remeron).\",\"breadcrumb\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/noradrenergic-and-specific-serotonergic-antidepressants-nassas\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.healthbenefitstimes.com\/glossary\/noradrenergic-and-specific-serotonergic-antidepressants-nassas\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/noradrenergic-and-specific-serotonergic-antidepressants-nassas\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Noradrenergic and specific serotonergic antidepressants (NaSSAs)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#website\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/\",\"name\":\"Glossary\",\"description\":\"Difinitions\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5\",\"name\":\"Glossary\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/author\/adminglossary\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Noradrenergic and specific serotonergic antidepressants (NaSSAs) - Definition of Noradrenergic and specific serotonergic antidepressants (NaSSAs)","description":"A class of atypical antidepressants that exert their effects by antagonizing presynaptic alpha2 receptors of both noradrenergic and serotonergic neurons, resulting in enhanced neurotransmission of norepinephrine and serotonin. NaSSAs are used primarily for the treatment of depression and anxiety disorders. An example of an NaSSA is mirtazapine (remeron).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.healthbenefitstimes.com\/glossary\/noradrenergic-and-specific-serotonergic-antidepressants-nassas\/","og_locale":"en_US","og_type":"article","og_title":"Noradrenergic and specific serotonergic antidepressants (NaSSAs) - Definition of Noradrenergic and specific serotonergic antidepressants (NaSSAs)","og_description":"A class of atypical antidepressants that exert their effects by antagonizing presynaptic alpha2 receptors of both noradrenergic and serotonergic neurons, resulting in enhanced neurotransmission of norepinephrine and serotonin. NaSSAs are used primarily for the treatment of depression and anxiety disorders. An example of an NaSSA is mirtazapine (remeron).","og_url":"https:\/\/www.healthbenefitstimes.com\/glossary\/noradrenergic-and-specific-serotonergic-antidepressants-nassas\/","og_site_name":"Glossary","article_published_time":"2020-07-14T05:41:32+00:00","author":"Glossary","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Glossary"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/noradrenergic-and-specific-serotonergic-antidepressants-nassas\/","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/noradrenergic-and-specific-serotonergic-antidepressants-nassas\/","name":"Noradrenergic and specific serotonergic antidepressants (NaSSAs) - Definition of Noradrenergic and specific serotonergic antidepressants (NaSSAs)","isPartOf":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#website"},"datePublished":"2020-07-14T05:41:32+00:00","dateModified":"2020-07-14T05:41:32+00:00","author":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5"},"description":"A class of atypical antidepressants that exert their effects by antagonizing presynaptic alpha2 receptors of both noradrenergic and serotonergic neurons, resulting in enhanced neurotransmission of norepinephrine and serotonin. NaSSAs are used primarily for the treatment of depression and anxiety disorders. An example of an NaSSA is mirtazapine (remeron).","breadcrumb":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/noradrenergic-and-specific-serotonergic-antidepressants-nassas\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.healthbenefitstimes.com\/glossary\/noradrenergic-and-specific-serotonergic-antidepressants-nassas\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/noradrenergic-and-specific-serotonergic-antidepressants-nassas\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.healthbenefitstimes.com\/glossary\/"},{"@type":"ListItem","position":2,"name":"Noradrenergic and specific serotonergic antidepressants (NaSSAs)"}]},{"@type":"WebSite","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#website","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/","name":"Glossary","description":"Difinitions","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.healthbenefitstimes.com\/glossary\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5","name":"Glossary","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/author\/adminglossary\/"}]}},"_links":{"self":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/28424","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/comments?post=28424"}],"version-history":[{"count":1,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/28424\/revisions"}],"predecessor-version":[{"id":28425,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/28424\/revisions\/28425"}],"wp:attachment":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/media?parent=28424"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/categories?post=28424"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/tags?post=28424"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}